1. Home
  2. BDTX vs RDZN Comparison

BDTX vs RDZN Comparison

Compare BDTX & RDZN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

N/A

Current Price

$1.38

Market Cap

104.0M

Sector

Health Care

ML Signal

N/A

Logo Roadzen Inc.

RDZN

Roadzen Inc.

N/A

Current Price

$0.96

Market Cap

87.7M

Sector

Finance

ML Signal

N/A

Company Overview

Basic Information
Metric
BDTX
RDZN
Founded
2014
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Blank Checks
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
104.0M
87.7M
IPO Year
2020
2021

Fundamental Metrics

Financial Performance
Metric
BDTX
RDZN
Price
$1.38
$0.96
Analyst Decision
Buy
Buy
Analyst Count
8
2
Target Price
★ $11.00
$5.00
AVG Volume (30 Days)
★ 766.3K
297.2K
Earning Date
11-10-2026
11-16-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 130.71
72.12
EPS
N/A
★ N/A
Revenue
N/A
★ $55,021,792.00
Revenue This Year
N/A
$41.04
Revenue Next Year
N/A
$78.38
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ 24.21
52 Week Low
$1.39
$0.94
52 Week High
$3.97
$2.56

Technical Indicators

Market Signals
Indicator
BDTX
RDZN
Relative Strength Index (RSI) 34.73 37.67
Support Level N/A N/A
Resistance Level $1.94 $1.27
Average True Range (ATR) 0.14 0.10
MACD -0.04 -0.01
Stochastic Oscillator 0.84 22.87

Price Performance

Historical Comparison
BDTX
RDZN

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

About RDZN Roadzen Inc.

Roadzen Inc is an insurance technology company on a mission to transform auto insurance powered by AI. Its clients comprise insurers, fleets, and carmakers to small fleets, brokers, and insurance agents that use Roadzen's technology to build new products, sell insurance, process claims, and improve road safety. The company's work in telematics and computer vision has earned recognition as an AI innovator by publications such as Forbes, Fortune, and Financial Express. Geographically, the company operates in India, United States of America, United Kingdom, and China. It generates maximum revenue form India.

Share on Social Networks: